Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i> -Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

Zhao Chen, Esra A. Akbay, Oliver R. Mikse, Tanya Tupper, Katherine A. Cheng, Yuchuan Wang, Xiaohong Tan, Abigail Altabef, Sue-Ann Woo, Liang Chen,

Clinical Cancer Research · 2013 · 60 citations · 24 references

DOIFull text

Open access

Concepts

Abstract

PURPOSE: To extend the results of a phase III trial in patients with non-small cell lung cancer with adenocarcinomas harboring EML4-ALK fusion. EXPERIMENTAL DESIGN: We conducted a co-clinical trial in a mouse model comparing the ALK inhibitor crizotinib to the standard-of-care cytotoxic agents docetaxel or pemetrexed. RESULTS: Concordant with the clinical outcome in humans, crizotinib produced a substantially higher response rate compared with chemotherapy, associated with significantly longer progression-free survival. Overall survival was also prolonged in crizotinib- compared with chemotherapy-treated mice. Pemetrexed produced superior overall survival compared with docetaxel, suggesting that this agent may be the preferred chemotherapy in the ALK population. In addition, in the EML4-ALK-driven mouse lung adenocarcinoma model, HSP90 inhibition can overcome both primary and acquired crizotinib resistance. Furthermore, HSP90 inhibition, as well as the second-generation ALK inhibitor TAE684, demonstrated activity in newly developed lung adenocarcinoma models driven by crizotinib-insensitive EML4-ALK L1196M or F1174L. CONCLUSIONS: Our findings suggest that crizotinib is superior to standard chemotherapy in ALK inhibitor-naïve disease and support further clinical investigation of HSP90 inhibitors and second-generation ALK inhibitors in tumors with primary or acquired crizotinib resistance.

References

24